AZD 3632
Alternative Names: AZD-3632Latest Information Update: 10 Feb 2026
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Menin inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Haematological malignancies
Most Recent Events
- 09 Jan 2026 Phase-I/II clinical trials in Haematological malignancies (In adolescents, In adults, In the elderly, Late-stage disease, Monotherapy, Second-line therapy or greater) in Germany (PO) (NCT07155226)
- 09 Jan 2026 Phase-I/II clinical trials in Haematological malignancies (In adolescents, In adults, In the elderly, Late-stage disease, Monotherapy, Second-line therapy or greater) in Germany (PO) (NCT07155226)
- 09 Jan 2026 Phase-I/II clinical trials in Haematological malignancies (In adolescents, In adults, In the elderly, Late-stage disease, Monotherapy, Second-line therapy or greater) in Japan (PO) (NCT07155226)